Article info
PDFOvarian Cancer
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial
- Address correspondence and reprint requests to Thomas J. Herzog, MD, University of Cincinnati Medical Center, UC Cancer Institute, 231 Albert Sabin Way, Suite 2005, Cincinnati, OH 45219. E-mail: thomas.herzog{at}uc.edu.
Citation
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial
Publication history
- Received January 21, 2016
- Accepted June 26, 2016
- First published November 1, 2016.
Online issue publication
November 01, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2016 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.